13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
November 2021 in “European Heart Journal Supplements” A woman with lupus had right heart failure due to blood clots in her lungs, but treatment improved her condition.
November 2021 in “European Heart Journal Supplements” SLE can increase the risk of blood clots, leading to heart failure, but treatment can improve heart function.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
Early recognition and aggressive treatment can significantly improve rare ANA-negative lupus with heart and skin issues.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
7 citations
,
August 2025 in “European Journal of Endocrinology” Long-term use of calcineurin inhibitors in transplant patients can cause hormone issues that can be managed with proper care.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
October 2021 in “Revista Medicina Cutánea Ibero-Latino-Americana” PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
49 citations
,
October 1988 in “The Journal of Clinical Endocrinology & Metabolism” Leuprolide effectively reduces hair growth in hirsute women at higher doses.
7 citations
,
July 2018 in “Biological & Pharmaceutical Bulletin” Phyllanthus urinaria extract may help treat hair loss by blocking a hair-related enzyme.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
13 citations
,
February 2022 in “JAMA Dermatology” Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
April 2014 in “Investigative Ophthalmology & Visual Science” 
61 citations
,
March 1981 in “Circulation” Minoxidil improves blood flow in heart failure patients.
9 citations
,
August 2023 in “Sexual Medicine Reviews” The effectiveness of platelet-rich plasma for erectile dysfunction is still unclear.
18 citations
,
September 2021 in “Colloids and surfaces. B, Biointerfaces” Nanoparticles can effectively deliver spironolactone to hair follicles for treating alopecia and acne.
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
17 citations
,
February 2019 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
50 citations
,
November 2021 in “Viruses” Spironolactone may help reduce COVID-19 severity in men by blocking harmful effects of certain hormones.
These medications for BPH have known risks and may have new side effects.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
17 citations
,
August 2001 in “Australasian journal of dermatology” A woman's liver problems improved after she stopped taking spironolactone.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.